2026-07-21T16:29:17Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/260062025-03-17T09:25:08Zcom_20.500.12105_2273com_20.500.12105_2202col_20.500.12105_19571

00925njm 22002777a 4500 dc Monteagudo, María author Calsina, Bruna author Salazar-Hidalgo, Milton E author Martínez-Montes, Ángel M author Piñeiro-Yáñez, Elena author Caleiras, Eduardo author Martín, Maria Carmen author Rodríguez-Perales, Sandra author Letón, Rocío author Gil, Eduardo author Buffet, Alexandre author Burnichon, Nelly author Fernández-Sanromán, Ángel author Díaz-Talavera, Alberto author Mellid, Sara author Arroba, Ester author Reglero, Clara author Martínez-Puente, Natalia author Roncador, Giovanna author Del Olmo, Maria Isabel author Corrales, Pedro José Pinés author Oliveira, Cristina Lamas author Álvarez-Escolá, Cristina author Gutiérrez, María Calatayud author López-Fernández, Adrià author García, Nuria Palacios author Regojo, Rita María author Díaz, Luis Robles author Laorden, Nuria Romero author Guadarrama, Oscar Sanz author Bechmann, Nicole author Beuschlein, Felix author Canu, Letizia author Eisenhofer, Graeme author Fassnacht, Martin author Nölting, Svenja author Quinkler, Marcus author Rapizzi, Elena author Remde, Hanna author Timmers, Henri J author Favier, Judith author Gimenez-Roqueplo, Anne-Paule author Rodriguez-Antona, Cristina author Currás-Freixes, Maria author Al-Shahrour, Fatima author Cascón, Alberto author Leandro-García, Luis J author Montero-Conde, Cristina author Robledo Batanero, Mercedes author 2024-12 Pheochromocytomas and paragangliomas are rare neuroendocrine tumours. Around 20-25 % of patients develop metastases, for which there is an urgent need of prognostic markers and therapeutic stratification strategies. The presence of a MAML3-fusion is associated with increased metastatic risk, but neither the processes underlying disease progression, nor targetable vulnerabilities have been addressed. We have compiled a cohort of 850 patients, which has shown a 3.65 % fusion prevalence and represents the largest MAML3-positive series reported to date. While MAML3-fusions mainly cause single pheochromocytomas, we also observed somatic post-zygotic events, resulting in multiple tumours in the same patient. MAML3-tumours show increased expression of neuroendocrine-to-mesenchymal transition markers, MYC-targets, and angiogenesis-related genes, leading to a distinct tumour microenvironment with unique vascular and immune profiles. Importantly, our findings have identified MAML3-tumours specific vulnerabilities beyond Wnt-pathway dysregulation, such as a rich vascular network, and overexpression of PD-L1 and CD40, suggesting potential therapeutic targets. Best Pract Res Clin Endocrinol Metab . 2024 Dec;38(6):101931. Best Pract Res Clin Endocrinol Metab 39218714 https://hdl.handle.net/20.500.12105/26006 MAML3 screening procedure MAML3-fusion metastasis paraganglioma pheochromocytoma tumour microenvironment vasculature MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma.